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Systemic inflammation is a causative factor in chronic pain. This is 
most obviously true for autoimmune diseases, such as rheuma- 
toid arthritis, where immune activity has a direct effect on tissue 
pathology.19 However, there is increasing evidence that in- 
flammatory mechanisms are implicated in chronic pain conditions 
outside the autoimmune domain. Notably, increased levels of 
proinflammatory cytokines have been found in fibromyalgia, 
chronic whiplash-associated disorder, and irritable bowel syn- 
drome, where objectively measurable tissue pathology is 
absent.3,10,17,24,34 However, most such studies are small, and 
the track record of replication is correspondingly poor. For 
instance, a systematic review found that although 2 or more 
studies reported elevated serum levels of interleukin (IL)-1RA, IL- 
6, and IL-8 in fibromyalgia, meta-analysis was significant for IL-6 
  only.36 In addition to sample size, many of these studies do not 
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control for lifestyle factors. This is particularly problematic in 
studies of clinical pain, as chronic pain may lead to insomnia, 
deconditioning, and obesity, which contribute to altered immune 
activity.2,29 There is therefore a real possibility of reverse causality. 
Clinical case studies are also unable to distinguish effects that are 
specific to the disease itself, such as cartilage degeneration in 
osteoarthritis, from more general neuroplastic changes in the 
peripheral and central nervous system. This is of major 
importance, as twin studies have found that the genetic 
mechanisms are largely the same for different pain pheno- 
types,38,39 suggesting that common molecular mechanisms can 
be identified, and treatments that span traditional diagnostic 
boundaries can be developed. 
Epidemiological studies of experimental pain sensitivity cir- 
cumvent or reduce many of the above limitations. They are 
typically large, can adequately control for lifestyle factors, and the 
possibility of reverse causality is considerably reduced. Moreover, 
associations between experimental pain and biomarkers that are 
observed in healthy individuals are more likely to reflect neuro- 
plastic changes than tissue-specific pathology. Finally, human 
experimental pain paradigms have close analogues in animal 
  
 
Two recent studies suggest that experimental pain sensitivity is associated with low-grade systemic inflammation. However, only 2 
biomarkers have been identified, and the studies were conducted in adult individuals where confounding effects of comorbid 
diseases cannot be excluded. We therefore tested associations between pain sensitivity and 119 inflammation-related serum 
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measure was cold-pressor pain tolerance (CPT), tested by placing the dominant hand in circulating cold (3˚C) water for a maximum 
of 105 seconds. Secondary outcomes were heat and pressure pain threshold and tolerance. Twelve proteins and 6 fatty acids were 
significantly associated with CPT after adjustment for possible confounding factors and correction for multiple comparisons. Of 
these, all fatty acids and 10 proteins were protective, ie, higher biomarkers levels were associated with increased CPT, whereas 2 
biomarkers were associated with lower tolerance. Taken together, these biomarkers predicted completion of the tolerance test with 
a C-statistic of 0.65. Results for heat and pressure pain tolerance were remarkably similar, strengthening the generalizability of our 
findings. In this cohort of young healthy individuals, we found a relationship between inflammation-related biomarkers and pain 
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models, where there is extensive evidence that neuroinflamma- 
tion induces neuroplastic changes resulting in central sensitiza- 
tion and widespread hyperalgesia.20,21,31,32 Descending pain 
modulatory systems arising in the brainstem are important in the 
maintenance of chronic pain and generalized hyperalgesia. 
Parallel findings in human studies of experimental pain would 
greatly increase the plausibility of generalizing from animals to 
humans. To the best of our knowledge, only 2 large-scale studies 
have examined relationships between inflammation and human 
experimental pain sensitivity. One found a positive correlation 
between cold-pressor tolerance and C-reactive protein (CRP) in 
a large adult sample.30 A second study, found that the v-3 
resolvin precursor 17-HDHA was associated with increased heat 
pain thresholds in a sample of adult twins.37 Although both 
studies suggest that pain sensitivity is associated with chronic 
low-grade inflammation, the number of biomarkers examined is 
limited. Furthermore, although the first of these studies controlled 
 
for chronic pain and lifestyle factors, residual confounding from 
acute pain conditions and nonpainful chronic conditions that 
affect pain sensitivity (eg, nonpainful neuropathies) cannot be 
excluded. Consequently, we aimed to analyse associations 
between a large number of proinflammatory and anti- 




2.1. Study design and population: Fit Futures 
In 2010 to 2011, all first-year upper-secondary school students in 
2 neighbouring municipalities in northern Norway attended the 
Tromsø Study: Fit Futures.40 The invited cohort included 1117 
adolescents, of which 1038 (530 boys) participated in the survey, 
providing an attendance rate of 92.9% (Fig. 1). Participants aged 





Figure 1. Study flowchart—the Tromsø Study, Fit Futures. *Excluded due to technical/procedural failures, medical reasons or lack of comprehension. 
 
 
excluded from the analysis due to possibly diverging biology, 
behaviour, or understanding of the test instructions. Furthermore, 
participants with inflammatory arthritis, fever, antibiotic use in the 
last 24 hours, or participants with high-sensitivity CRP .10 mg/L, 
which mirror other acute or chronic diseases, were also excluded. 
 
 
2.2. Study assessments 
2.2.1. Clinical interview and questionnaires 
Information about medical history, medication use, fever, or other 
symptoms of ongoing infection were obtained through a clinical 
interview performed by trained nurses at the Clinical Research 
Department, University Hospital of North Norway, Tromsø. All 
reported chronic diseases were encoded according to ICD-10 
nomenclature. Height and weight were measured to the nearest 
0.1 cm and 0.1 kg, respectively, on an electronic scale (Jenix DS 
102 stadiometer; Dong Sahn Jenix, Co, Ltd, Seoul, Korea) with 
the participants wearing light clothing and no shoes. Body mass 
index (BMI) was calculated using the formula weight/height2 
(kg/m2). Participants filled in a web-based questionnaire on 
lifestyle and general health, including pubertal development. No 
girls were pregnant. Participants were classified regarding their 
tobacco use into 4 categories: Nonusers of any tobacco 
products; users of snuff only; smokers only; and users of both 
snuff and smoke. The short version of the Alcohol Use Disorders 
Identification Test for Consumption (AUDIT-C) was used for 
screening of alcohol misuse, and cutoff scores of 7 for boys and 5 
for girls were used.11 The participants indicated their level of 
leisure-time physical activity in the past year using 1 of 4 response 
categories: sedentary: reading, watching television, or engaging 
in sedentary activities; light: at least 4 hours a week walking, 
bicycling, or engaging in other types of physical activity; 
moderate: at least 4 hours a week exercising to keep fit and 
participating in recreational athletics; and vigorous: regular, 
vigorous training or participating in competitive sports several 
times a week. The Short Mood and Feelings Questionnaire 
(SMFQ) was used to screen for depressive symptoms, and    a 
cutoff score of $11 was applied.23 
 
2.2.2. Blood sampling and biomarker analysis 
The participants provided nonfasting blood samples, obtained 
from the antecubital vein in BD vacutainer tubes with no additive 
(Becton, Dickinson and Company, Franklin Lakes, NJ). Serum 
was transferred to Supelco glass vials (Sigma-Aldrich Norway AS, 
Oslo, Norway) with Pasteur glass pipettes. The serum samples 
were stored at 270˚C and thawed only once for biomarker 
analyses. 
Serum levels of 92 inflammatory proteins were analysed by 
Protein Extension Array Technology (Proseek Multiplex Inflam- 
mation panel; Olink Bioscience, Uppsala, Sweden), which was 
used for relative quantification of proteins. Briefly, 3-mL in- 
cubation mix containing 2 Proximity Extension Assay (PEA) 
probes, that is, antibodies equipped with single-strand DNA 
oligonucleotide, against each protein was mixed with 1-mL serum 
and incubated at 8˚C overnight. The mixture was then added 
96-mL extension mix, containing PEA enzyme and PCR reagents, 
and incubated for 5 minutes at room temperature before the plate 
was transferred to a thermal cycler for 17 cycles of DNA 
amplification. A 96.96 Dynamic Array IFC (Fluidigm, South San 
Francisco, CA) was prepared and primed according to the 
manufacturer’s instructions. Furthermore, 2.8 mL of sample 
mixture was added to 7.2-mL detection mix in a new 96-well 
plate, and 5 mL was loaded into the right side of the primed 96.96 
Dynamic Array IFC. The unique primer pairs for each cytokine 
were loaded into the left side of the 96.96 Dynamic Array IFC, and 
the protein expression program was run in Fluidigm Biomark 
reader according to the instructions for Proseek. 
Serum levels of 27 fatty acids (FAs) were analysed by Gas 
Chromatography with Flame Ionization Detector (GC-FID) (Vitas AS, 
Oslo, Norway), which was used for absolute quantification of FAs. 
Serum samples, thawed in fridge overnight, are vortexed, centrifuged, 
and pipetted into vials. Internal standard (triheptadecanoin) is added, 
and samples are methylated with 3 N MeOH HCl. Fatty acid methyl 
esters (FAMEs) are extracted with hexane, and then samples are 
neutralized with 3 N KOH in water. After mixing and centrifuging, the 
hexane phase is injected into the GC-FID. Analysis is performed on 
a 7890A GC with a split/splitless injector, a 7683B automatic liquid 
sampler, and flame ionization detection (Agilent Technologies, Palo 
Alto, CA). Separations are performed on a SP-2380 (30 3 0.25-mm 
internal diameter 3 0.25-mm film thickness) column from Supelco. 
 
2.2.3. Pain sensitivity testing 
An experimental sensory testing session was conducted to 
assess responses to 3 stimulus modalities, applied in the 
following order: pressure, heat, and cold-pressor. The test  
protocol was based on methodology adapted from the sixth 
Tromsø Study, demonstrating feasibility.33,35 
 
2.2.3.1. Cold-pressor test 
Adolescents were asked to submerge their nondominant hand 
and  wrist  in  a  13-L  plexiglass  container  connected  with  a 
circulating cold (3˚C) water bath (Julabo PF40-HE; JULABO 
Labortechnik GmbH, Seelbach, Germany) for as long as they 
were able to, up to a maximum of 105 seconds (cold-pressor 
test). Time from immersion of hand and wrist to withdrawal was 
recorded as the cold-pressor pain tolerance (CPT). 
 
2.2.3.2. Heat pain threshold and tolerance 
Heat pain threshold and tolerance were assessed using a MEDOC 
ATS somatosensory stimulator with a 30 3 30-mm thermode 
(Medoc Ltd, Ramat Yishai, Israel). Heat stimuli were applied to the 
volar surface of the adolescent’s nondominant forearm, starting at 
a baseline temperature of 32˚C, increasing by 1˚C/s, to a maximum 
temperature of 50˚C. During pain threshold assessment, adoles- 
cents were instructed to press a button as soon as the sensation 
changed from warmth to pain, at which point the thermode 
returned to baseline at a rate of 8˚C/s. A total of 3 trials were 
conducted, and the second and third trials were averaged for use 
in further analyses. To assess heat pain tolerance, the same 
stimulus procedure was used, but this time, the participants were 
instructed to press the button when they were unable to tolerate 
the pain any further. Two tolerance trials were conducted, and the 
average of these was used in further analysis. 
 
2.2.3.3. Pressure pain threshold and tolerance 
Threshold and tolerance assessments were made at 2 sites on 
the participants’ nondominant arm: on the cuticle of the ring 
fingernail and on the trapezius muscle, midway between the 
shoulder joint and the neck. Pressure pain threshold and 
tolerance were assessed using a handheld computerized 
pressure algometer with a circular 1-cm2 probe (AlgoMed, 
Medoc Ltd.). All stimuli started at 0 kPa and increased by 30 
kPa per second, up to a maximal pressure of 1000 kPa. For 
pressure pain threshold assessment, the participant was 
 
 
instructed to press a button when the sensation changed from 
pressure to pain, at which point the probe was removed. A total of 
3 thresholds were obtained at each site, and the average of the 
second and third measurements was used in further analyses. 
For pain tolerance assessments, the participants were instructed 
to press the button when they were unable to withstand the pain. 
Two tolerance assessments were made at each site (finger and 





The primary outcome was CPT chosen based on previous 
research showing the relationship between hs-CRP and wide- 
spread hyperalgesia in a population-based cohort.1,30 Secondary 




2.4. Statistical analysis 
Statistical analysis was conducted using R version 3.4.3 (R 
Foundation for Statistical Computing, Vienna, Austria). 
Statistical significance was set at the 0.05 level. To correct 
for multiple testing, a Benjamini–Hochberg false discovery 
rate (FDR) of 0.05 was applied.5 Biomarkers detected in 
$70% of the samples were included in the statistical 
analyses. Serum levels were z-score standardized using the 
population mean and SD. We modelled the effect of 
biomarkers on CPT with Cox proportional hazard regressions 
models with endurance time as the timescale and withdrawal 
of the hand from the water bath as the event and the 
maximum time (105 seconds) as the censoring point. Initially, 
we tested for sex interactions in models including the 
biomarker, sex, and sex 3 biomarker as predictors. For 
biomarkers where the sex interaction term was significant at 
P , 0.05 (uncorrected), all further analyses were stratified by 
sex. For biomarkers with nonsignificant sex interaction, the 
sex interaction term was omitted in further analyses. First, we 
modelled the crude risk for each biomarker, adjusting for sex 
in nonstratified analyses (model 1). Second, these analyses 
were repeated, adjusting for putative confounders (model 2): 
 
BMI, tobacco use, alcohol consumption, depressive symp- 
toms, and physical activity outside school. Third, in post hoc 
analyses, we modelled biomarker effects on secondary 
outcomes, heat and pressure pain threshold, and tolerance 
at fingernail and trapezius with linear regression and Cox 
proportional hazard regressions models, respectively. Only 
biomarkers that were significantly associated with CPT were 
included in these analyses. Finally, we investigated the 
discriminatory power of the proportional hazards model of 
the biomarker candidates significant in the primary analysis, 
which was assessed by the concordance probability (c- 
index) defined by Gö nen and Heller15 using the GPE-package 
in R. The c-index is most familiar from logistic regression, 
where it is also known as the area under the receiver- 
operating curve. A c-index of 1 corresponds to a model with 
perfect discrimination and a value of 0.5 corresponds to  a 
model with no discriminative ability. 
 
2.5. Ethics 
Data collection for The Tromsø Study: Fit Futures was approved 
by the Regional Committee for Medical and Health Research 
Ethics (reference number 2011/1702/REK-Nord). The study 
procedures were conducted in accordance with the Declaration 
of Helsinki. Before any examination, written informed consent 




3.1. General description of sample 
Descriptive characteristics of the participants in the study are 
shown in Table 1. Half the participants (53%) completed the cold- 
pressor test without withdrawing their hand before the test 
ended. We observed sex differences where 53.2% girls vs 42.2% 
boys withdrew their hand before time was up (P 5 0.002). In the 
entire study population lower CPT was found among tobacco- 
users compared with nonusers (P , 0.001), as well as among 
participants who were physically inactive outside school com- 
pared with physically active (P 5 0.001). Depressive symptoms 
and BMI were not associated with CPT. 
 
 
Descriptive characteristics of cold-pressor tolerance (CPT) groups. Fit Futures. 
 Girls (n 5 385)   Boys (n 5 436)   Both (n 5 821)  
CPT <105 s CPT 5 105 s  CPT <105 s CPT 5 105 s  CPT <105 s CPT 5 105 s 
(n 5 201) (n 5 184)  (n 5 186) (n 5 250)  (n 5 387) (n 5 434) 
Body mass index (BMI), kg/m2, mean (SD) 21.8 (3.5) 22.9 (4.7)  22.5 (4.4) 22.2 (3.6)  22.1 (4.0) 22.5 (4.1) 
Tobacco use, n (%)         
Never users of any tobacco 108 (58.1) 133 (75.6)  84 (47.7) 159 (67.9)  191 (53.1) 292 (71.2) 
Ever users of snuff only 40 (21.5) 29 (16.5)  46 (26.4) 42 (18.0)  86 (23.9) 71 (17.3) 
Ever smokers only 14 (7.5) 5 (2.8)  8 (4.6) 5 (2.1)  22 (6.1) 10 (2.5) 
Ever users of both snuff and smoke 24 (12.9) 9 (5.1)  37 (21.3) 28 (12.0)  61 (16.9) 37 (9.0) 
Alcohol use (hazardous), n (%) 59 (29.6) 38 (20.7)  33 (18.1) 40 (16.2)  92 (24.1) 78 (18.1) 
Emotional distress, n (%), HSCL-10 $1.85 29 (14.6) 26 (14.1)  19 (10.3) 11 (4.5)  48 (12.5) 37 (8.6) 
Physical activity level in the past year, n (%)         
Sedentary 26 (13.1) 21 (11.4)  74 (40.2) 55 (22.3)  100 (26.1) 76 (17.7) 
Light physical activity 90 (45.2) 62 (33.7)  46 (25.0) 54 (21.8)  136 (35.5) 116 (26.9) 
Moderate physical activity 59 (29.6) 59 (32.1)  41 (22.3) 60 (24.3)  100 (26.1) 119 (27.6) 
Vigorous physical activity 24 (12.1) 42 (22.8)  23 (12.5) 78 (31.6)  47 (12.3) 120 (27.8) 

















































































































































3.2. Biomarkers correlating with cold-pressor pain tolerance 
In total, 74/92 proteins and 27/27 FAs were detectable in $70% 
of the sample and were included in the analyses. Results of Cox 
regression analysis, unadjusted model revealed a relationship of 
12 proteins and 6 FAs with CPT after correction for FDR (Fig. 2). 
Of these, all FAs and 10 proteins reduced the risk for aborting the 
cold-pressor test, ie, higher biomarkers levels were associated 
with increased CPT, whereas 2 biomarkers (CCL28 and FGF21) 
were associated with lower CPT. The concordance probability (c- 
index) of the 18 biomarkers predicting CPT was estimated to 0.65 
(SE 5 0.012) indicating fair discriminatory power. The above 
relationships remained significant after adjusting for BMI, tobacco 
or alcohol use, depression, and physical activity (Table 2). 
 
 
3.3. Biomarkers correlating with heat and pressure pain 
threshold and tolerance 
Biomarkers that were significantly associated with CPT were 
tested for associations with heat and pressure pain threshold and 
tolerance. Although the number of statistically significant asso- 
ciations was lower than in the regression model for the primary 
outcome, it is notable that the direction of effect was identical for 
all biomarkers when tested for heat and pressure pain tolerance 
(Figs. 2 and 3). Despite of more heterogeneous results for heat 
and pressure pain thresholds, all 6 FAs shown in Figure 4 were 
associated with higher thresholds for heat pain (although they did 
not reach significance). Results from the adjusted Cox regression 
model for heat and pressure pain threshold and tolerance are 





This large population-based study among adolescents revealed 
a relationship between 18 inflammation-related serum bio- 
markers and pain sensitivity. Overall, 12 proteins and 6 FAs were 
statistically significant associated with CPT. These relationships 
remained unchanged after adjusting for BMI, tobacco or alcohol 
use, depression, and physical activity. Furthermore, results were 
remarkably similar for 2 other pain tolerance measures, strength- 
ening the generalizability of our findings. 
Pain is considered as 1 of 4 cardinal signs of inflammation, and 
mediators of the inflammatory response are well known to 
modulate both short- and long-term pain sensitivity.13 The close 
relationship between nociceptors and immune cells is evidenced 
by the shared expression of many cytokine-, growth factor- (GF), 
and toll-like receptors.28 A wide range of molecules can affect 
pain sensitivity, including ions, prostaglandins, hormones, GFs, 
cytokines, and lipids,16,28 thus complicating the search for 
correlations between single biomarkers and pain tolerance. 
Transmission from animals to human research is also challeng- 
ing. In our approach, we simultaneously screened for 119 
inflammation-related proteins and FAs and detected their 
association with pain sensitivity. Cytokines involved in the 
regulation of the innate immune system, cellular processes, and 
signal transduction represented our main findings. Cytokines are 
produced as a response to pathogens or during injury and include 
both inflammatory and resolving mediators. This response not 
only recruit immune cell, but can also have a long-term effect on 
the sensitivity of nociceptors by interactions with surface 
receptors on the neuron. Interestingly, many of these cytokines 
have previously been associated with pain—eg, stem cell 




















Figure 2. Forest plot showing the hazard ratio (HR) and 95% CI for cold-pressor pain tolerance (CPT), and heat and pressure pain tolerance, Fit Futures. Serum 
levels of the biomarkers were z-score standardized. *Unique identifier is either the protein number in accordance with the UniProt Knowledgebase or the carbon 
chain number of the fatty acid. Only variables significantly associated with CPT after Benjamini–Hochberg false detection rate (FDR-adjusted) with threshold, P # 
0.05, are shown. CI, confidence interval. 
 
 
and eIF4EBP1.22 Adding to the complexity, peripheral and local 
concentrations can have opposite effects on pain sensitivity (ie, 
leukemia inhibitory factor receptor (LIFR)).25 Urokinase-type 
plasminogen activator showed the strongest positive association 
with CPT. Urokinase-type plasminogen activator has an impor- 
tant role in the regulation of inflammation, immunity, and 
coagulation through interactions with urokinase-type plasmino- 
gen activator receptor. Urokinase-type plasminogen activator/ 
urokinase-type plasminogen activator receptor promotes tissue 
remodeling through activation of plasmin and metalloproteinases 
and recruits circulating leukocytes through interactions with 
endothelial integrins.7 Stem cell factor and PD-L1, secreted by 
endothelial cells and dorsal root ganglions, respectively, disturb 
pain signal transduction in the sensory neuron by affecting ion 
channels. Stem cell factor interacts with the receptor c-Kit, 
expressed on neurons. The hyperalgestic effect of this interaction 
depends on the TRPV1 cation channel.26 PD-L1, typically 
secreted by cancer cells, activates the receptor PD-1 and 
inhibits neuronal activities by modulating sodium and potassium 
channels.9 The protein with the strongest negative association 
with CPT in our study was C-C motif chemokine 28 (CCL28). 
CCL28 is expressed by mucosa-associated epithelial cells in 
the gut, trachea, and salivary glands. It plays dual roles in 
mucosal immunity as an antimicrobial agent and as a chemo- 
attractant for CC-chemokine receptor 10 (CCR10)-expressing 
immune cells. The expression is modulated by proinflammatory 
cytokines and bacterial products such as lipopolysacchar- 
ides.18 Thus, epithelial inflammation is associated with CCL28 
production. 
The acute inflammatory response is counterbalanced by   a 
complex process termed resolution where apoptosis of 




Figure 3. Hazard ratios (HRs) for aborting the test for cold-pressor pain tolerance (CPT), and heat and pressure pain tolerance sorted by HR of CPT, Fit Futures. 





Figure 4. Forest plot showing standardized betas and 95% CI for heat and pressure pain threshold, Fit Futures. Serum levels of the biomarkers were z-score 
standardized. *Unique identifier is either the protein number in accordance with the UniProt Knowledgebase or the carbon chain number of the fatty acid. Only 
variables significantly associated with CPT after Benjamini–Hochberg false detection rate (FDR adjusted) with threshold, P # 0.05, are shown. CI, confidence 
interval; CPT, cold-pressor pain tolerance. 
 
 
anti-inflammatory mechanisms. Endogenous proteins/peptides 
and lipid mediators including v-3 FA derived “specialized 
proresolution mediators” such as lipoxins, resolvins (Rvs), 
maresins, and protectins released by a number of cell types 
orchestrate the resolution of inflammation and tissue repair. 





Figure 5. Correlations among biomarkers. Color scale: red 5 highest positive correlation, white 5 no correlation, blue 5 highest negative correlation. Serum levels 
of the biomarkers were z-score standardized. Only variables significantly associated with CPT after Benjamini–Hochberg false detection rate (FDR adjusted) with 




release of inflammatory mediators from immune cells, inhibition of 
ion channels, and by affecting signaling cascades in dorsal root 
ganglion and presynaptic and postsynaptic neurons. The v-3 
FAs docosahexaenoic acid (DHA) and eicosapentaenoic acid 
(EPA) originate the D- and E-series Rvs, respectively. Recent 
studies have highlighted the importance of RvD1 and RvE1 in 
acute and persistent tissue inflammation in animal models.6,41 
The RvD1-6, neuroprotection D1, actively reverses inflammatory 
pain in mice.4 We found strong positive associations of DHA and 
EPA with higher CPT suggesting a protective role of these FAs in 
the modulation of pain sensitivity. Clinical trials have previously 
shown that v-3 FAs supplementation is protective in selected 
phenotypes (eg, rheumatoid arthritis).12 Our findings suggest that 
RCTs investigating the effect of dietary supplements on chronic 
pain and hyperalgesia are warranted. 
In addition, this study showed lower pain tolerance among 
girls, smokers, and/or snuff users, as well as among 
participants physically inactive outside school. Sex differences 
are commonly reported in pain research, providing evidence of 
higher prevalence of widespread pain as well as greater 
sensitivity to experimental pain among girls/women.14 We also 
found some sex interactions in the association between 
biomarkers and pain sensitivity (stem cell factor, PD-L1, and 
FGF23). Interestingly, the function of these proteins have all 
been demonstrated to be regulated downstream of estrogen 
signaling cascades.8,14,42 However, the relationship between 
hormones, inflammatory biomarkers, and pain sensitivity 
needs further studies. 
 
4.1. Study strengths and limitations 
The strengths of our study are its size and the population-based 
design including high attendance rates in both sexes. Because of 
participants’ age and exclusion of adolescents with inflammatory 
disease or ongoing infection, these data are considered valid for 
the investigation of inflammation-related pain mechanisms. 
However, our study has some limitations. Because of the 
cross-sectional design, conclusions about causality cannot be 
drawn. Second, no adjustment was made for unmeasured 
factors, such as dietary status possibly related to socioeconomic 
status  of  parents  (confounding).  Nevertheless,  .50%  of  the 
variance in cold-pressor responses can be explained by genetic 
factors27; therefore, the relative contribution of the environment is 
limited. Third, nonfasting blood samples may be subject to bias. 
Fourth, our study was unable to demonstrate a pivotal role of IL-6, 
IL-1b, and TNF-a in pain sensitivity despite preclinical evidence 
that these cytokines sensitize the peripheral nerve endings that 
lead to hyperalgesia. Fifth, our study was limited to a multiplex 
panel of preselected inflammatory biomarkers, and many putative 




In summary, we found a relationship between inflammation- 
related biomarkers and pain tolerance in this cohort of young 
healthy individuals. Biomarkers with anti-inflammatory and 
analgesic effects predominated, suggesting that the develop- 
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